Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoSAKOM: My-Rept in Kidney Transplant
NCT03794492Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate mofetil in kidney transplant rejection, sponsored by Chong Kun Dang Holdings. Primary endpoint: Donor-Specific Anti-HLA Antibody at 36 months. Started Mar 2018; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03794492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794492.